HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a price target of $32.
May 24, 2024 | 11:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Iovance Biotherapeutics and maintained a price target of $32, indicating confidence in the company's future performance.
The reiteration of a Buy rating and a maintained price target of $32 by HC Wainwright & Co. suggests strong confidence in Iovance Biotherapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100